Illumina shares fall 9.79% after hours as Q4 results fail to allay investor concerns over China challenges and.

Illumina

Illumina: JP Morgan Lowers Price Target to $120 from $130 to Neutral.

Illumina shares fall 11.48% intraday as analysts cut price targets amid Q4 results.

Illumina Sets 2026 Revenue Guidance at $4.5B-$4.6B

Illumina Q4 Revenue Up 5% to $1.159 Billion

Catalyst<ul> <li>Recent Bearish Engulfing and Long Lower Shadow signals suggest strong bullish sentiment in technical indicators.</li> <li>Analysts split between Neutral and Strong Buy ratings indicate growing institutional optimism about ILMN.</li> <li>Fund flows show positive net inflow for medium, large, and extra-large orders indicating institutional accumulation.</li></ul>Risk<ul> <li>Technical indicators show a volatile market with unclear direction, making it difficult to identify strong trends.</li> <li>Cash-MV remains a negative factor, indicating the company's cash reserves are relatively low compared to market value.</li></ul>

Key Factors

Illumina (ILMN) Q4 2025 revenue rose 5% YoY to $1.16 billion, with clinical consumables revenue up 20% ex-China. Illumina provided 2026 revenue guidance of $4.5–4.6 billion, below expectations for stronger growth, amid China-related headwinds and SomaLogic acquisition dilution. Illumina shares fell over 8.7% intraday following Q4 results, reflecting investor skepticism about long-term growth and bearish analyst sentiment. Illumina acquired SomaLogic for $363.7 million from Standard BioTools, enhancing its multiomics and clinical genomics strategy.

ILMN News